Study further expands clinical development program of Bayer’s long-acting reversible intrauterine system Mirena® (levonorgestrel-releasing intrauterine system) 52 mg. Approximately 121 out of every ...

Nearly half of all pregnancies in the United States are unin- tended,1 which is defined as any pregnancy either mistimed, unplanned, or unwanted.2,3 Prior studies on unintended preg- nancy in the ...

Please provide your email address to receive an email when new articles are posted on . Levonorgestrel-releasing intrauterine system users vs. nonusers had an increased risk for breast cancer. Breast ...

The MarketWatch News Department was not involved in the creation of this content. ROSWELL, Ga., Oct. 15, 2025 /PRNewswire/ -- Sebela Women's Health Inc., a part of Sebela Pharmaceuticals, today ...

Credit: Shutterstock. By the end of the 6th year, Mirena should be removed and replaced if continued use is desired. The Food and Drug Administration (FDA) has approved the supplemental New Drug ...

Women who use copper intrauterine devices (IUD) as a form of birth control may be at lower risk for high-grade cervical cancer compared with those who use a levonorgestrel-releasing intrauterine ...

Hazard ratios were 1.3, 1.4, and 1.8 for 0 to 5, 5 to 10, and more than 10 to 15 years of use, respectively, compared with the corresponding durations of nonuse, resulting in an excess of 14, 29, and ...

BEDFORD, Mass.--(BUSINESS WIRE)--Rejoni, Inc., a privately held clinical-stage company, today announced the completion of enrollment of 150 patients in the Juveena Hydrogel pivotal clinical study.

SAN FRANCISCO and DUBLIN, Oct. 28, 2019 /PRNewswire/ -- Medicines360, a global nonprofit organization with a mission to expand women's access to quality medicines, and Allergan plc (NYSE: AGN), a ...

Low-dose levonorgestrel-releasing intrauterine system (LNG-IUS) 13.5 mg and 19.5 mg is associated with a significantly lower risk of first-time depression vs high dose LNG-IUS 52 mg. Overall, 46,565 ...

The Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Mirena (levonorgestrel-releasing intrauterine system; Bayer), to extend the indication to up to 6 ...